Rebrova, D. V., Sleptsov, I. V., Chernikov, R. A., Chinchuk, I. K., Rusakov, V. F., Krasnov, L. M., Fedorov, E. A., Semenov, A. A., Savelyeva, T. V., Loginova, O. I., Shikhmagomedov, S. S., Vorokhobina, N. V., Kalugina, V. V., & Fogt, S. N. (2024). Adrenocortical Cancer. Results of Examination of Patients at the Clinic of High Medical Technologies. Voprosy Onkologii, 70(1), 88–95. https://doi.org/10.37469/0507-3758-2024-70-1-88-95

Abstract

Materials and Methods. The article describes the results of the examination of 76 patients with adrenocortical cancer (ACC), who have undergone surgery in the in-patient facility of the N.I. Pirogov Clinic of High Medical Technologies of St. Petersburg State University. ACC was diagnosed from 2009 to 2020. Patient demographic data, baseline disease characteristics, tumor hormonal activity, and computed tomography (CT) data were described.

Results. Overall, the data obtained were consistent with the international literature with respect to age at onset of the disease (median age 45 years), the ratio of females to males (3:1), and the incidence of hypercortisolism (48.8 %). It was found that the combination of radiographic density ≤ 20 HU and mass size less than 4 cm does not exclude all cases of ACC. According to the findings 2 (3.3 %) of 65 patients would not be diagnosed if the above criteria had been used. Within the CT data analysis, about one-third of patients showed no increase in the standard thresholds for absolute and relative percentage washout (RPW) that defines malignancy. The results analysis revealed that the subgroup of patients with Cushing syndrome had a statistically significant increase in contrast washout rates.

Conclusion. Overall, the findings in ACC patients in the studied population are consistent with the literature data. The study results suggest that the diagnostic value of contrast washout parameters for differential diagnosis of ACC is limited, especially in patients with small tumors and with Cushing syndrome. According to the data obtained, the most reliable criterion for excluding ACR is native tumor radiodensity < 10 HU; the use of this criterion made it possible to exclude all cases of ACC.

https://doi.org/10.37469/0507-3758-2024-70-1-88-95

##article.numberofdownloads## 57

##article.numberofviews## 223

pdf (Русский)

References

Podbregar A., Janez A., Goricar K., Jensterle M. The prevalence and characteristics of non-functioning and autonomous cortisol secreting adrenal incidentaloma after patients’ stratification by body mass index and age. BMC Endocrine Disorders. 2020; 20(1): 118.-DOI: https://doi.org/10.1186/s12902-020-00599-0.

Fassnacht M., Assie G., Baudin E., et al. Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020; 31(11): 1476-1490.-DOI: https://doi.org/10.1016/j.annonc.2020.08.2099.

Libé R. Adrenocortical carcinoma (ACC): diagnosis, prognosis, and treatment. Front Cell Dev Biol. 2015; 3: 45.-DOI: https://doi.org/10.3389/fcell.2015.00045.

Fassnacht M., Johanssen S., Quinkler M., et al. Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification. Cancer. 2009; 115(2): 243-250.-DOI: https://doi.org/10.1002/cncr.24030.

Araújo A.N., Bugalho M.J. Advanced adrenocortical carcinoma: Current perspectives on medical treatment. Horm Metab Res. 2021; 53(5): 285-292.-DOI: https://doi.org/10.1055/a-1453-0806.

Shariq O.A., McKenzie T.J. Adrenocortical carcinoma: current state of the art, ongoing controversies, and future directions in diagnosis and treatment. Ther Adv Chronic Dis. 2021; 12: 20406223211033104.-DOI: https://doi.org/10.1177/20406223211033103.

Bancos I., Taylor A.E., Chortis V., et al. Urine steroid metabolomics for the differential diagnosis of adrenal incidentalomas in the EURINE-ACT study: a prospective test validation study. Lancet Diabetes Endocrinol. 2020; 8(9): 773-781.-DOI: https://doi.org/10.1016/S2213-8587(20)30218-7.

Viëtor C.L., Creemers S.G., van Kemenade F.J., et al. How to Differentiate Benign from Malignant Adrenocortical Tumors? Cancers (Basel). 2021; 13(17): 4383.-DOI: https://doi.org/10.3390/cancers13174383.

Dinnes J., Bancos I., Ferrante di Ruffano L., et al. Management of endocrine disease: Imaging for the diagnosis of malignancy in incidentally discovered adrenal masses: a systematic review and meta-analysis. Eur J Endocrinol. 2016; 175(2): R51-64.-DOI: https://doi.org/10.1530/EJE-16-0461.

Fassnacht M., Dekkers O., Else T., et al. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2018; 179(4): G1–G46.-DOI: https://doi.org/10.1530/EJE-18-0608.

Korobkin M., Brodeur F.J., Francis I.R., et al. CT time-attenuation washout curves of adrenal adenomas and nonadenomas. AJR Am J Roentgenol. 1998; 170(3): 747-752.-DOI: https://doi.org/10.2214/ajr.170.3.9490968.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.